March 29, 2024

New drugs for psoriatic arthritis: Latest medications – Medical News Today

0

Treatment for psoriatic arthritis (PsA) may involve nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), or biological therapies. Over the past few years, several new drugs have received approval for use as a treatment for this condition.

…….

Treatment for psoriatic arthritis (PsA) may involve nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), or biological therapies. Over the past few years, several new drugs have received approval for use as a treatment for this condition.

Almost one-third of people with psoriasis develop PsA. The condition most commonly develops in people ages 30โ€“50 years. The onset may be gradual and mild, or it may be more sudden with severe symptoms.

Rheumatologists and dermatologists are typically those who treat PsA. Treatment aims to reduce pain and swelling, help the joints work correctly, and prevent ongoing joint damage.

This article looks at newly approved drugs for treating PsA, some medications still in clinical trials, and other treatments for the condition.

Over the past few years, the Food and Drug Administration (FDA) has approved several new drugs to treat PsA. The sections below look at these in more detail.

Tofacitinib

In 2017, the FDA approved the first Janus kinase (JAK) inhibitor medication, tofacitinib (Xeljanz), for treating PsA. JAK inhibitors are small-molecule medications that a person takes orally.

JAK inhibitors work by blocking the activity of JAK enzymes, which stimulate the production of inflammatory proteins called cytokines.

Some evidence suggests that tofacitinib is as effective as other biologic medications for people whose conditions have not responded to DMARDs. It also offers an alternative to injectable therapies.

Golimumab

In 2017, the FDA approved a new tumor necrosis factor-alpha (TNF-alpha) inhibitor called golimumab to treat PsA. TNF-alpha inhibitors work by targeting TNF, a protein that causes inflammation.

A 2020 study investigated the effectiveness of golimumab as a first-, second-, and third-line biologic treatment for PsA. It was an effective treatment in all cases โ€” particularly for first-line treatment participants, with 76.4% entering remission after 24 months.

Guselkumab

The FDA approved the use of guselkumab (Tremfya), a new interleukin blocker, for the treatment of PsA in 2020.

It is the first treatment for PsA that specifically targets interleukin-23 (IL-23), which is a cytokine associated with inflammation in PsA. A 2021 review and meta-analysis compared the effectiveness of guselkumab with that of other interleukin blockers as well as several TNF inhibitors.

The review concludes that guselkumabโ€™s effectiveness is comparable with the other treatments and offers a better response than many in improving skin symptoms.

A separate study suggested it was particularly effective in helping participants with inflammation of the sacroiliac joints, which include those in the spine and pelvis.

Abatacept

In 2017, the FDA approved the use of a new T cell inhibitor for PsA called abatacept (Orencia). T cells play a role in …….

Source: https://www.medicalnewstoday.com/articles/new-drugs-for-psoriatic-arthritis

Leave a Reply

Your email address will not be published. Required fields are marked *